

AMENDMENT TO THE CLAIMS

Pursuant to 37 C.F.R. §1.121, the following is a complete listing of the claims of the present application. The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-54. (Canceled)

55. (Currently amended) An antibody comprising a monoclonal antibody that specifically binds to an antigenic epitope of human IL-22RA (SEQ ID NO: 3) amino acid number 1 (Pro), to amino acid number 6 (Asp) of SEQ ID NO: 3; wherein the antibody reduces ~~or neutralizes~~ the activity of either human IL-22 (SEQ ID NO: 6) or IL-20 (SEQ ID NO: 8).

56. (Original) The antibody of claim 55, wherein the antibody reduces or neutralizes the activity of both human IL22 (SEQ ID NO:6) and IL-20 (SEQ ID NO:8).

57. (Currently amended) The antibody of claim 55 or 56, wherein the antibody is selected from the group consisting of: (a) a murine monoclonal antibody, (b) a humanized antibody derived from (a), (c) an antibody fragment, and (d) a human monoclonal antibody.

58. (Original) The antibody of claim 57, wherein the antibody further comprises pegylation.

59-80. (Canceled)

81. (New) The antibody of claim 55, wherein the antibody reduces the activity of human IL-22 (SEQ ID NO: 6).

82. (New) The antibody of claim 55, wherein the antibody neutralizes the activity of either human IL-22 (SEQ ID NO: 6) or IL-20 (SEQ ID NO: 8).

83. (New) The antibody of claim 82, wherein the antibody neutralizes the activity of human IL-22 (SEQ ID NO: 6).

84. (New) The antibody of claim 57, wherein the antibody is a humanized antibody.

85. (New) The antibody of claim 57, wherein the antibody is a human antibody.

86. (New) An antibody fragment that specifically binds to an antigenic epitope of human IL-22RA (SEQ ID NO: 3) amino acid number 1 (Pro), to amino acid number 6 (Asp) of SEQ ID NO: 3; wherein the antibody fragment reduces the activity of either human IL-22 (SEQ ID NO: 6) or IL-20 (SEQ ID NO: 8).

87. (New) The antibody fragment of claim 86, wherein the fragment is selected from the group consisting of F(ab')₂, F(ab)₂, Fab', Fab, Fv and scFv.

88. (New) An antibody that specifically binds to a polypeptide comprising a sequence having one conservative amino acid substitution relative to a sequence set forth in SEQ ID NO:3 amino acid number 1 (Pro) to amino acid number 6 (Asp), wherein the antibody reduces the activity of either human IL-22 (SEQ ID NO: 6) or IL-20 (SEQ ID NO: 8).

89. (New) A pharmaceutical composition comprising the antibody of claim 55 and a pharmaceutically acceptable carrier.